TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT03617484

Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

Cause of deathStaffing, sites or logistics, also regulatory or ethics Automatic label, confidence 0.5, unverified. How labels are made.
“Enrollment and/or interactions/interventions temporarily paused due to COVID-19 and expected to resume in the future. This is not a suspension of IRB approval.”

The sponsor’s own words in the registry.

Life of this trial

2018201920202021Registered2018-07-31Withdrawn (as of)2020-06-22Planned start2020-07 (planned)

Vital statistics

Status
Withdrawn
Phase
Phase 2
Sponsor
University of Michigan Rogel Cancer Center
Sponsor type
University, hospital or other
Conditions
Mantle Cell Lymphoma
Interventions
Bortezomib; Ibrutinib
Participants
0
Sites
1
Countries
United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.